NasdaqGS:IBRXBiotechs
Early Glioblastoma Trial Success Might Change the Case for Investing in ImmunityBio (IBRX)
In late August 2025, ImmunityBio announced early results from a pilot study in recurrent glioblastoma showing that all five patients treated with its investigational immunotherapy regimen achieved disease control, with three responding and two displaying stable disease.
This small cohort result is particularly eye-catching because glioblastoma is a challenging cancer with a very low five-year survival rate, especially among older adults.
We'll explore how the enthusiasm generated by 100%...